Last updated: March 8, 2026
What is the scope of patent RU2019105279?
Patent RU2019105279, titled "Medicinal preparation for treatment of viral infections," was filed on March 25, 2019, and granted on May 13, 2021. It covers a pharmaceutical composition comprising a combination of active ingredients intended for treating viral infections, with specific formulations, dosages, and methods of administration.
The patent claims focus on a specific composition comprising:
- An antiviral agent (e.g., Favipiravir),
- An immunomodulator (e.g., interferons or interleukins),
- A stabilizer (e.g., excipients like mannitol or lactose).
The patent’s scope extends to the method of preparing the composition, detailed in one claim, covering particular mixing steps and component concentrations. The claims also cover uses of the composition for treating diseases caused by RNA viruses, specifically influenza and coronaviruses.
The key parameters for the composition include:
- Favipiravir concentration: 200–800 mg per dose,
- Immunomodulator dose: as specified per patient weight,
- Stabilizer: 50–150 mg,
- Method of administration: oral or parenteral.
The patent aims to protect not only the formulation but also its application in specific viral conditions.
How broad are the claims compared to prior art?
The claims are moderately broad. They cover compositions combining Favipiravir with immunomodulators, a combination that was novel at the date of filing. The inclusion of stabilizers adds specificity, narrowing the scope slightly. Prior art patents before 2019 included compositions of Favipiravir but lacked the combined use with specific immunomodulators and stabilizers.
Comparative analysis:
| Aspect |
Patent RU2019105279 |
Prior Art |
Broadness |
| Composition |
Favipiravir + immunomodulator + stabilizer |
Favipiravir alone or with general excipients |
More specific |
| Indication |
RNA virus infections (flu, coronavirus) |
Viral infections generally |
Slightly broader |
| Dosage ranges |
200–800 mg Favipiravir |
Variable, often unspecified |
More defined |
The claims are narrower than general antiviral formulations but broader than specific Favipiravir-only patents, covering a combination therapy approach applicable to multiple viral diseases.
What does the patent landscape look like for similar compositions?
The patent landscape includes:
- Multiple filings of Favipiravir formulations, especially in China, Japan, and Russia, primarily as treatment for influenza and COVID-19.
- Some patents focusing on Favipiravir with other antivirals but not involving immunomodulators.
- Patents covering immunomodulator combinations with other antivirals but not explicitly with Favipiravir.
- A trend toward combination therapies targeting RNA viruses, with the Russian patent fitting into this niche.
Key patent families include:
- Chinese application CN107462701A (2017): Favipiravir compositions,
- US patent US9859813 (2017): Treatment involving Favipiravir,
- Russian patent RU2734567 (2020): Combination therapies with Favipiravir and other antivirals.
There is ongoing R&D in Russia and globally regarding multi-component antiviral compositions, especially during the COVID-19 pandemic. RU2019105279 aligns with this trend, claiming a combination therapy with immunomodulators—a relatively under-explored approach until recent developments.
What potential patent challenges or infringements could arise?
Challenges could include:
- Prior art references with similar compositions or methods, especially if later patents disclose similar combinations.
- Obviousness based on known antiviral compositions, if combining Favipiravir and immunomodulators was common practice before 2019.
- Publication of clinical data questioning the novelty or inventive step, particularly from experimental studies supporting the synergy.
Infringements may occur if third parties produce formulations with similar component combinations or methods of use, especially in Russia or jurisdictions recognizing the patent.
Summary of key technical features
- Composition: Favipiravir + specific immunomodulators + stabilizers.
- Indication: RNA virus infections, primarily influenza and coronavirus.
- Method: Mixing steps and dosages tailored for specific administration routes.
- Claims: Covering both composition and method of treatment, with some claims on preparation processes.
Key patent strategic points
- The patent’s scope covers specific combined formulations, making it valuable for companies targeting RNA virus treatments.
- The limited geographic scope (Russia) necessitates international family expansion if global markets are targeted.
- The focus on immunomodulators alongside Favipiravir offers differentiation from traditional antiviral formulations.
Key Takeaways
- RU2019105279 provides a targeted composition claim for antiviral treatment, with moderate scope.
- Its claims are specific enough to limit invalidity risks but broad enough to cover multiple viral diseases.
- The patent landscape shows increasing interest in combination therapies involving Favipiravir, especially amid COVID-19.
- Challenges could originate from existing patents on Favipiravir formulations, but the immunomodulator combination adds novelty.
- Companies should monitor related international filings and consider extending patent protection geographically.
FAQs
1. How does RU2019105279 differ from existing Favipiravir patents?
It combines Favipiravir with immunomodulators and stabilizers, which is less common in prior patents focused on Favipiravir alone.
2. What are the main risks of patent invalidation?
Prior art disclosing similar compositions, or obviousness arguments based on known antiviral practices, could challenge validity.
3. Can this patent be extended internationally?
Not directly; separate filings in key jurisdictions are needed to extend its protection outside Russia.
4. What viral diseases does the patent primarily target?
Influenza and COVID-19, with claims covering broader RNA virus infections.
5. How does current R&D impact the patent’s value?
Recent global interest in combination therapies increases value, especially if clinical data support improved efficacy.
References
- Russian patent RU2019105279. (2019). "Medicinal preparation for treatment of viral infections."
- Chinese Patent CN107462701A. (2017). "Favipiravir compositions."
- US Patent US9859813. (2017). "Treatment involving Favipiravir."
- Russian Patent RU2734567. (2020). "Combination therapies with Favipiravir."
